3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Small Cell Lung Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Doxorubicin
9
Imatinib Mesylate
6
pazopanib
4
Ifosfamide
4
Radiotherapy
3
Gemcitabine
3
Docetaxel
3
pembrolizumab
2
Radiation
2
Neoadjuvant Therapy
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
selinexor
1
saracatinib
1
sapanisertib
1
ribociclib
1
peposertib
1
liposomal doxorubicin
1
indolepropanol phosphate
1
envafolimab
1
cixutumumab
1
brigimadlin
1
avelumab
1
X-Rays
1
Watchful Waiting
1
TTI-621
1
Sunitinib
1
Specimen Handling
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Dermatofibrosarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts